OncoMatch/Clinical Trials/NCT05113368
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Is NCT05113368 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Regorafenib and Fulvestrant for ovarian cancer.
Treatment: Regorafenib · Fulvestrant — To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anti-angiogenesis therapy
Exception: bevacizumab allowed
Prior anti-angiogenesis therapy is not allowed except for bevacizumab
Cannot have received: regorafenib or other agents with similar multi-targeted kinase activity (regorafenib)
Prior use of regorafenib or other agents with similar multi-targeted kinase activity
Lab requirements
Blood counts
Platelet count >100000 /mm3, hemoglobin (Hb) >9 g/dL, absolute neutrophil count (ANC)> 1500/mm3
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement)
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Serum creatinine ≤ 1.5 x ULN; Platelet count >100000 /mm3, hemoglobin (Hb) >9 g/dL, absolute neutrophil count (ANC)> 1500/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05113368 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-angiogenesis therapy, regorafenib or other agents with similar multi-targeted kinase activity disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages